Drugs / CORT108297
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04452500 | Oct 2022 → Dec 2026 expected | post-traumatic stress disorder | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2 | NCT04601038 | Jun 2021 → Nov 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Johns Hopkins University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CORT108297 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04601038 ↗ |
| Known as | ADS-108297 | ChEMBL registry synonym — accepted as the source's own label CHEMBL271220 ↗ |
| Action | Inhibit | “Glucocorticoid receptor antagonist” CHEMBL271220 ↗1“which blocks the hormone cortisol” NCT04452500 ↗ |
| Modality | Small molecule | — CHEMBL271220 ↗ |
| Target | NR3C1 | “Glucocorticoid receptor antagonist” CHEMBL271220 ↗ |